Present topline Phase I/II data per the statistical analysis plan
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Jun 2025
- Due
- 30 Sep 2025
- Delivered
- September 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“present topline Phase I/II data per the SAP”
What we found
Evidence strength A What the grades mean
The company announced positive topline data from the Phase I/II studies of AMT-130 in September 2025, which aligns with the commitment to present data per the statistical analysis plan by Q3 2025.
-
A uniQure N.V. 10-Q filed 2025-11-10
“The Phase I/II AMT-130 clinical trials were supplemented by two additional protocols, each with a statistical plan that was discussed with and submitted to the United States Food and Drug Administration” ✓ confirmed on the page
-
A uniQure N.V. 10-Q filed 2026-05-05
“In September 2025, we announced positive topline data from the three-year analysis of the ongoing Phase I/II studies of AMT-130 for the treatment of Huntington’s disease.” ✓ confirmed on the page
Market reaction: the shares moved +14.9% against the S&P 500 over the three sessions around the disclosure (4 May 2026 to 7 May 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- Topline Phase I/II clinical data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-QURE-001913 · Corrections policy